Published in J Gen Virol on August 01, 1994
Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A (1995) 4.15
Prophylactic human papillomavirus vaccines. J Clin Invest (2006) 2.36
How will HPV vaccines affect cervical cancer? Nat Rev Cancer (2006) 2.23
Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. J Virol (1995) 2.13
Binding and internalization of human papillomavirus type 33 virus-like particles by eukaryotic cells. J Virol (1995) 1.70
Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol (1996) 1.66
Expression of the human papillomavirus type 11 L1 capsid protein in Escherichia coli: characterization of protein domains involved in DNA binding and capsid assembly. J Virol (1997) 1.58
Human papillomavirus type 11 recombinant L1 capsomeres induce virus-neutralizing antibodies. J Virol (1998) 1.49
Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol (1998) 1.48
Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice. Infect Immun (1997) 1.38
Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol (2002) 1.35
Prevalence of antibodies to human papillomavirus (HPV) type 16 virus-like particles in relation to cervical HPV infection among college women. Clin Diagn Lab Immunol (1997) 1.34
DNA-induced structural changes in the papillomavirus capsid. J Virol (2001) 1.29
Replication and assembly of human papillomaviruses. J Dent Res (2009) 1.20
Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol (2003) 1.09
Human papillomavirus virus-like particles are efficient oral immunogens when coadministered with Escherichia coli heat-labile enterotoxin mutant R192G or CpG DNA. J Virol (2001) 1.02
Perspectives for preventive and therapeutic HPV vaccines. J Formos Med Assoc (2010) 0.99
Evidence of prior exposure to human bocavirus as determined by a retrospective serological study of 404 serum samples from adults in the United States. Clin Vaccine Immunol (2009) 0.92
Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer. Biologics (2008) 0.92
HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol (2013) 0.89
Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol (2007) 0.88
Identification of neutralizing conformational epitopes on the human papillomavirus type 31 major capsid protein and functional implications. Protein Sci (2009) 0.86
HPV vaccination to prevent cervical cancer and other HPV-associated disease: from basic science to effective interventions. J Clin Invest (2016) 0.81
Prophylactic HPV vaccines. J Clin Pathol (2007) 0.80
Lessons learned from successful human vaccines: Delineating key epitopes by dissecting the capsid proteins. Hum Vaccin Immunother (2015) 0.79
Self-assembly of in vitro-translated human papillomavirus type 16 L1 capsid protein into virus-like particles and antigenic reactivity of the protein. Clin Diagn Lab Immunol (1996) 0.79
Progress in the development of a cervical cancer vaccine. Ther Clin Risk Manag (2006) 0.78
The role of vaccines in the control of STDs: HPV vaccines. Genitourin Med (1996) 0.77
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med (1996) 4.43
A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med (1982) 4.04
Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol (1993) 4.00
Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF. Genes Dev (1992) 2.90
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial. N Engl J Med (1990) 2.52
NIH conference. Herpes zoster-varicella infections in immunosuppressed patients. Ann Intern Med (1978) 2.52
Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis. J Infect Dis (1982) 2.26
Treatment of recurrent genital herpes simplex infections with oral acyclovir. A controlled trial. JAMA (1984) 2.20
Double-blind placebo-controlled trial of oral acyclovir in first-episode genital herpes simplex virus infection. JAMA (1984) 1.94
Serological differentiation of human papillomavirus types 11, 16 and 18 using recombinant virus-like particles. J Gen Virol (1994) 1.60
Dose response of cold-adapted, reassortant influenza A/California/10/78 virus (H1N1) in adult volunteers. J Infect Dis (1984) 1.57
Two E2 binding sites (E2BS) alone or one E2BS plus an A/T-rich region are minimal requirements for the replication of the human papillomavirus type 11 origin. J Virol (1993) 1.50
Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis (1995) 1.47
Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors. J Infect Dis (2000) 1.46
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother (2000) 1.42
The duration of zidovudine benefit in persons with asymptomatic HIV infection. Prolonged evaluation of protocol 019 of the AIDS Clinical Trials Group. JAMA (1994) 1.41
Intralesional recombinant alpha-2 interferon for the treatment of patients with condyloma acuminatum or verruca plantaris. Arch Dermatol (1986) 1.37
Single-dose cefuroxime axetil in the treatment of uncomplicated gonorrhea: a controlled trial. Sex Transm Dis (1986) 1.21
Topically administered acyclovir in the treatment of recurrent herpes simplex genitalis: a controlled trial. J Infect Dis (1983) 1.21
A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis (2001) 1.20
Antibody-mediated neutralization of human papillomavirus type 11 (HPV-11) infection in the nude mouse: detection of HPV-11 mRNAs. J Infect Dis (1992) 1.20
In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16. J Virol (1998) 1.20
Treatment of condyloma acuminatum with three different interferons administered intralesionally. A double-blind, placebo-controlled trial. Ann Intern Med (1988) 1.19
Detection of infection by human papillomavirus in genital condylomata. A comparison study using immunocytochemistry and in situ nucleic acid hybridization. Am J Clin Pathol (1988) 1.17
Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis (1995) 1.16
Serologic response to treatment of syphilis in patients with HIV infection. Arch Intern Med (1996) 1.13
Highly active antiretroviral therapy results in a decrease in CD8+ T cell activation and preferential reconstitution of the peripheral CD4+ T cell population with memory rather than naive cells. Antiviral Res (1998) 1.13
Radioimmunoassay for detection of the Snow Mountain Agent of viral gastroenteritis. J Med Virol (1986) 1.10
Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol (2002) 1.09
Propagation of human papillomavirus type 11 in human xenografts using the severe combined immunodeficiency (SCID) mouse and comparison to the nude mouse model. Virology (1993) 1.09
Use of human papillomavirus type 11 virions in an ELISA to detect specific antibodies in humans with condylomata acuminata. J Gen Virol (1991) 1.09
Serum antibody responses in naturally occurring influenza A virus infection determined by enzyme-linked immunosorbent assay, hemagglutination inhibition, and complement fixation. J Clin Microbiol (1983) 1.08
Comparison of direct fluorescent antibody, acridine orange, wet mount, and culture for detection of Trichomonas vaginalis in women attending a public sexually transmitted diseases clinic. Sex Transm Dis (1989) 1.07
Expression in Escherichia coli of seven DNA fragments comprising the complete L1 and L2 open reading frames of human papillomavirus type 6b and localization of the 'common antigen' region. J Gen Virol (1989) 1.07
Isolation of Chlamydia trachomatis from men with urethritis: relative value of one vs. two swabs and influence of concomitant gonococcal infection. Sex Transm Dis (1986) 1.06
Expression of the full-length products of the human papillomavirus type 6b (HPV-6b) and HPV-11 L2 open reading frames by recombinant baculovirus, and antigenic comparisons with HPV-11 whole virus particles. J Gen Virol (1990) 1.03
Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med (1990) 1.03
Epidemiology of genital herpes simplex virus infection. Epidemiol Rev (1985) 1.02
2',3'-Dideoxyinosine in patients with AIDS or AIDS-related complex. Rev Infect Dis (1990) 0.98
Antibody response to human papillomavirus (HPV) type 11 in children with juvenile-onset recurrent respiratory papillomatosis (RRP). Virology (1992) 0.97
Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis (1990) 0.97
Cell-mediated cytotoxicity in recurrent herpes simplex virus infections in man. Proc Soc Exp Biol Med (1977) 0.96
Multiple-dose pharmacokinetics of oral zidovudine in hemophilia patients with human immunodeficiency virus infection. Antimicrob Agents Chemother (1990) 0.96
Pharmacokinetics of orally administered zidovudine among patients with hemophilia and asymptomatic human immunodeficiency virus (HIV) infection. Antiviral Res (1989) 0.95
Human immunodeficiency virus (HIV-1) gp160-specific lymphocyte proliferative responses of mononuclear leukocytes from HIV-1 recombinant gp160 vaccine recipients. J Infect Dis (1991) 0.94
Failure of recommended treatment for secondary syphilis. JAMA (1986) 0.94
Disseminated aspergillosis presenting with endophthalmitis. A case report and a review of the literature. Cancer (1984) 0.93
Double-blind, placebo-controlled trial comparing long-term suppressive with short-term oral acyclovir therapy for management of recurrent genital herpes. Am J Med (1988) 0.93
Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse. J Virol (1998) 0.93
Pneumonic and nonpneumonic forms of legionellosis. The result of a common-source exposure to Legionella pneumophila. Arch Intern Med (1982) 0.93
HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol (1997) 0.92
Photo quiz. Chronic cutaneous verrucous varicella-zoster infection. Clin Infect Dis (1998) 0.92
Prolonged, but not diminished, zidovudine absorption induced by a high-fat breakfast. Pharmacotherapy (1995) 0.90
Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. J Infect Dis (1999) 0.90
Penile intraepithelial neoplasia: clinical presentation and an analysis of the physical state of human papillomavirus DNA. J Infect Dis (1993) 0.86
Didanosine (ddI) and zidovudine (ZDV) susceptibilities of human immunodeficiency virus (HIV) isolates from long-term recipients of ddI. Antiviral Res (1993) 0.85
Actinomyces naeslundii as an agent of pelvic actinomycosis in the presence of an intrauterine device. J Clin Microbiol (1985) 0.85
Lymphocyte populations in acute viral gastroenteritis. Infect Immun (1976) 0.85
Evolution of the antibody response to human papillomavirus type 11 (HPV-11) in patients with condyloma acuminatum according to treatment response. J Med Virol (1993) 0.85
Neisseria elongata subsp. elongata, a case of human endocarditis complicated by pseudoaneurysm. J Clin Microbiol (1996) 0.84
Comparative rates of sexually transmitted diseases among heterosexual men, homosexual men, and heterosexual women. Sex Transm Dis (1985) 0.82
Intravenous and oral zidovudine pharmacokinetics and coagulation effects in asymptomatic human immunodeficiency virus-infected hemophilia patients. Antimicrob Agents Chemother (1992) 0.82
Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 0.81
Persisting human immunodeficiency virus type 1 gp160-specific human T lymphocyte responses including CD8+ cytotoxic activity after receipt of envelope vaccines. J Infect Dis (1993) 0.81
Results of a screening program for Chlamydia trachomatis infection in men attending a sexually transmitted diseases clinic. Sex Transm Dis (1997) 0.80
Failure of cefotaxime treatment in an adult with Streptococcus pneumoniae meningitis. Am J Med (1997) 0.80
Design of therapeutic studies in herpes simplex encephalitis. Lancet (1985) 0.79
Cell-mediated cytotoxicity following influenza infection and vaccination in humans. J Med Virol (1979) 0.78
Herpes simplex virus-induced immunespecific interferon production by cryopreserved human peripheral blood mononuclear leukocytes. J Immunol Methods (1986) 0.78
Interferon alpha-n1 (Wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy. Antiviral Res (1988) 0.78
Efficacy and safety of 0.5% podofilox solution in the treatment and suppression of anogenital warts. Am J Med (1994) 0.78
Taxonomy of the human papillomaviruses. Clin Infect Dis (1993) 0.78
Evaluation of temperature sensitivity of human papillomavirus type 11 by using the human xenograft severe combined immunodeficiency mouse model. J Clin Microbiol (1994) 0.77
Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res (2000) 0.77
A randomized, double-blind trial of parenteral low dose versus high dose interferon-beta in combination with cryotherapy for treatment of condyloma acuminatum. Antiviral Res (1997) 0.77
In vitro interactions between bovine papillomavirus and human monocytes and macrophages. Intervirology (1991) 0.76
Single-dose trospectomycin for chlamydial urethritis in men. Antimicrob Agents Chemother (1991) 0.75
Differences in early ultrastructural aspects of the replication of measles and subacute sclerosing panencephalitis viruses in a cell culture from a human astrocytoma. J Neuropathol Exp Neurol (1980) 0.75
Didanosine: long-term follow-up of patients in a phase 1 study. Clin Infect Dis (1993) 0.75
A Markov model for a clinical episode of recurrent genital herpes. Biometrics (1987) 0.75
Viral pneumonias. Med Clin North Am (1980) 0.75
Comment: papillomaviruses not in herpes group; fluorouracil in condyloma. Drug Intell Clin Pharm (1987) 0.75
A double-blind, placebo-controlled cytogenetic study of oral acyclovir in patients with recurrent genital herpes. J Infect Dis (1991) 0.75